Immunoregulation of experimental autoimmune encephalomyelitis by the selective CB1 receptor antagonist

Journal of Neuroscience Research

Volumn 90, Issue 1, 2012, Pages 84-95

  Lou, Zhi Yin ^a   Zhao, Chong Bo ^b   Xiao, Bao Guo ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Cannabinoid receptor; Experimental autoimmune encephalomyelitis; Inflammatory responses; Neuroprotection; Selective CB1R antagonist

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; FRACTALKINE; FREUND ADJUVANT; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; RIMONABANT; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; MACROPHAGE; MICROGLIA; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPINAL CORD; SPLEEN; WEIGHT REDUCTION; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; EMBRYO, MAMMALIAN; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HIPPOCAMPUS; MICE; MICE, INBRED C57BL; NEUROGLIA; NEURONS; PEPTIDE FRAGMENTS; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RNA, MESSENGER; SPINAL CORD; SPLEEN;

EID: 81255152003     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22721     Document Type: Article

References (66)

1. Alkaitis MS, Solorzano C, Landry RP, Piomelli D, DeLeo JA, Romero-Sandoval EA. 2010. Evidence for a role of endocannabinoids, astrocytes and p38 phosphorylation in the resolution of postoperative pain. PLoS One 5: e10891.
2. Amantea D, Spagnuolo P, Bari M, Fezza F, Mazzei C, Tassorelli C, Morrone LA, Corasaniti MT, Maccarrone M, Bagetta G. 2007. Modulation of the endocannabinoid system by focal brain ischemia in the rat is involved in neuroprotection afforded by 17beta-estradiol. FEBS J 274: 4464-4775.
3. Baker D, Pryce G, Giovannoni G, Thompson AJ. 2003. The therapeutic potential of cannabis. Lancet Neurol 2: 291-298.
4. Benito C, Romero JP, Tolon RM, Clemente D, Docagne F, Hillard CJ, Guaza C, Romero J. 2007. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci 27: 2396-2402.
5. Berrendero F, Sanchez A, Cabranes A, Puerta C, Ramos JA, Garcia-Merino A, Fernandez-Ruiz J. 2001. Changes in cannabinoid CB1 receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse 41: 195-202.
6. Bilsland LG, Dick JR, Pryce G, Petrosino S, Di Marzo V, Baker D, Greensmith L. 2006. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J 20: 1003-1005.
7. Borner C, Hollt V, Kraus J. 2007. Activation of human T cells induces upregulation of cannabinoid receptor type 1 transcription. Neuroimmunomodulation 14: 281-286.
8. Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, Shire D, Le Fur G, Casellas P. 1993. Cannabinoid-receptor expression in human leukocytes. Eur J Biochem 214: 173-180.
9. Cabral GA, Marciano-Cabral F. 2005. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J Leukoc Biol 78: 1192-1197.
10. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, Huang D, Kidd G, Dombrowski S, Dutta R, Lee JC, Cook DN, Jung S, Lira SA, Littman DR, Ransohoff RM. 2006. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 9: 917-924.
11. Carlisle SJ, Marciano-Cabral F, Staab A, Ludwick C, Cabral GA. 2002. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol 2: 69-82.
12. Centonze D, Bari M, Rossi S, Prosperetti C, Furlan R, Fezza F, De Chiara V, Battistini L, Bernardi G, Bernardini S, Martino G, Maccarrone M. 2007. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain 130: 2543-2553.
13. Chen CC, Zechariah A, Hsu YH, Chen HW, Yang LC, Chang C. 2008. Neuroaxonal ion dyshomeostasis of the normal-appearing corpus callosum in experimental autoimmune encephalomyelitis. Exp Neurol 210: 322-330.
14. Chuchawankul S, Shima M, Buckley NE, Hartmann CB, McCoy KL. 2004. Role of cannabinoid receptors in inhibiting macrophage costimulatory activity. Int Immunopharmacol 4: 265-278.
15. Croxford JL. 2003. Therapeutic potential of cannabinoids in CNS disease. Cns Drugs 17: 179-202.
16. Croxford JL, Miller SD. 2003. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55, 212. J Clin Invest 111: 1231-1240.
17. Croxford JL, Yamamura T. 2005. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J Neuroimmunol 166: 3-18.
18. De Jesus ML, Hostalot C, Garibi JM, Salles J, Meana JJ, Callado LF. 2010. Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas. Neurochem Int 56: 829-833.
19. Devane WA, Dysarz FR, Johnson MR, Melvin LS, Howlett AC. 1988. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34: 605-613.
20. Di Marzo V, Bisogno T, De Petrocellis L, Brandi I, Jefferson RG, Winckler RL, Davis JB, Dasse O, Mahadevan A, Razdan RK, Martin BR. 2001. Highly selective CB1 cannabinoid receptor ligands and novel CB1/VR1 vanilloid receptor "hybrid" ligands. Biochem Biophys Res Commun 281: 444-451.
21. Falenski KW, Carter DS, Harrison AJ, Martin BR, Blair RE, DeLorenzo RJ. 2009. Temporal characterization of changes in hippocampal cannabinoid CB1 receptor expression following pilocarpine-induced status epilepticus. Brain Res 1262: 64-72.
22. Fernandez-Lopez D, Martinez-Orgado J, Nunez E, Romero J, Lorenzo P, Moro MA, Lizasoain I. 2006. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats. Pediatr Res 60: 169-173.
23. Hatakeyama M, Imaizumi T, Tamo W, Yamashita K, Yoshida H, Fukuda I, Satoh K. 2004. Heparin inhibits IFN-gamma-induced fractalkine/CX3CL1 expression in human endothelial cells. Inflammation 28: 7-13.
24. Howlett AC. 2002. The cannabinoid receptors. Prostaglandins Other Lipid Mediat 68/69: 619-631.
25. Huang D, Shi FD, Jung S, Pien GC, Wang J, Salazar-Mather TP, He TT, Weaver JT, Ljunggren HG, Biron CA, Littman DR, Ransohoff RM. 2006. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J 20: 896-905.
26. Imaizumi T, Matsumiya T, Fujimoto K, Okamoto K, Cui X, Ohtaki U, Hidemi, Yoshida, Satoh K. 2000. Interferon-gamma stimulates the expression of CX3CL1/fractalkine in cultured human endothelial cells. Tohoku J Exp Med 192: 127-139.
27. Iversen L. 2003. Cannabis and the brain. Brain 126: 1252-1270.
28. Jackson SJ, Diemel LT, Pryce G, Baker D. 2005a. Cannabinoids and neuroprotection in CNS inflammatory disease. J Neurol Sci 233: 21-25.
29. Jackson SJ, Pryce G, Diemel LT, Cuzner ML, Baker D. 2005b. Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation. Neuroscience 134: 261-268.
30. Kaminski NE, Abood ME, Kessler FK, Martin BR, Schatz AR. 1992. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol Pharmacol 42: 736-742.
31. Kanazawa N, Nakamura T, Tashiro K, Muramatsu M, Morita K, Yoneda K, Inaba K, Imamura S, Honjo T. 1999. Fractalkine and macrophage-derived chemokine: T cell-attracting chemokines expressed in T cell area dendritic cells. Eur J Immunol 29: 1925-1932.
32. Killestein J, Polman C. 2004. The therapeutic value of cannabinoids in MS: real or imaginary? Mult Scler 10: 339-340.
33. Killestein J, Uitdehaag BM, Polman CH. 2004. Cannabinoids in multiple sclerosis: do they have a therapeutic role? Drugs 64: 1-11.
34. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, Friedman H. 2003. The cannabinoid system and immune modulation. J Leukoc Biol 74: 486-496.
35. Loria F, Petrosino S, Mestre L, Spagnolo A, Correa F, Hernangomez M, Guaza C, Di Marzo V, Docagne F. 2008. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur J Neurosci 28: 633-641.
36. Loria F, Petrosino S, Hernangomez M, Mestre L, Spagnolo A, Correa F, Di Marzo V, Docagne F, Guaza C. 2010. An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. Neurobiol Dis 37: 166-176.
37. Maccarrone M, Gasperi V, Catani MV, Diep TA, Dainese E, Hansen HS, Avigliano L. 2010. The endocannabinoid system and its relevance for nutrition. Annu Rev Nutr 30: 423-440.
38. Mackie K. 2008. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol 20( Suppl 1): 10-14.
39. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN. 2005. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 95: 437-445.
40. Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C, Cheng X, Carrier EJ, Mann MK, Giovannoni G, Pertwee RG, Yamamura T, Buckley NE, Hillard CJ, Lutz B, Baker D, Dittel BN. 2007. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 13: 492-497.
41. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutierrez SO, van der Stelt M, Lopez-Rodriguez ML, Casanova E, Schutz G, Zieglgansberger W, Di Marzo V, Behl C, Lutz B. 2003. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302: 84-88.
42. Martinez-Orgado J, Fernandez-Lopez D, Lizasoain I, Romero J. 2007. The seek of neuroprotection: introducing cannabinoids. Rec Pat CNS Drug Discov 2: 131-139.
43. Matias I, Pochard P, Orlando P, Salzet M, Pestel J, Di Marzo V. 2002. Presence and regulation of the endocannabinoid system in human dendritic cells. Eur J Biochem 269: 3771-3778.
44. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564.
45. Muthian S, Rademacher DJ, Roelke CT, Gross GJ, Hillard CJ. 2004. Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neuroscience 129: 743-750.
46. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, Greenberg DA. 1999. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 19: 2987-2995.
47. Navarrete M, Araque A. 2008. Endocannabinoids mediate neuron-astrocyte communication. Neuron 57: 883-893.
48. Ni X, Geller EB, Eppihimer MJ, Eisenstein TK, Adler MW, Tuma RF. 2004. Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult Scler 10: 158-164.
49. Nilsson O, Fowler CJ, Jacobsson SO. 2006. The cannabinoid agonist WIN 55, 212-2 inhibits TNF-alpha-induced neutrophil transmigration across ECV304 cells. Eur J Pharmacol 547: 165-173.
50. Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A, Shohami E. 2006. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis 22: 257-264.
51. Parmentier-Batteur S, Jin K, Mao XO, Xie L, Greenberg DA. 2002. Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci 22: 9771-9775.
52. Pertwee RG. 1997. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74: 129-180.
53. Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A, Thompson AJ, Giovannoni G, Cuzner ML, Baker D. 2003. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126: 2191-2202.
54. Rodriguez DFF, Del AI, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. 2005. The endocannabinoid system: physiology and pharmacology. Alcohol Alcoholism 40: 2-14.
55. Ronco AM, Llanos M, Tamayo D, Hirsch S. 2007. Anandamide inhibits endothelin-1 production by human cultured endothelial cells: a new vascular action of this endocannabinoid. Pharmacology 79: 12-16.
56. Shan S, Hong-Min T, Yi F, Jun-Peng G, Yue F, Yan-Hong T, Yun-Ke Y, Wen-Wei L, Xiang-Yu W, Jun M, Guo-Hua W, Ya-Ling H, Hua-Wei L, Ding-Fang C. 2011. NEW evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease. Neurobiol Aging 32: 443-458.
57. Shouman B, Fontaine RH, Baud O, Schwendimann L, Keller M, Spedding M, Lelievre V, Gressens P. 2006. Endocannabinoids potently protect the newborn brain against AMPA-kainate receptor-mediated excitotoxic damage. Br J Pharmacol 148: 442-451.
58. Smith PF. 2010. New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids. Ther Clin Risk Manag 6: 59-63.
59. Sunnemark D, Eltayeb S, Nilsson M, Wallstrom E, Lassmann H, Olsson T, Berg AL, Ericsson-Dahlstrand A. 2005. CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin. J Neuroinflamm 2: 17.
60. Thaera GM, Wellik KE, Carter JL, Demaerschalk BM, Wingerchuk DM. 2009. Do cannabinoids reduce multiple sclerosis-related spasticity? Neurologist 15: 369-371.
61. Trojano M. 2007. Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis? Neurology 69: 1478-1479.
62. van der Stelt M, Di Marzo V. 2005. Cannabinoid receptors and their role in neuroprotection. Neuromol Med 7: 37-50.
63. Van der Walt A, Butzkueven H, Kolbe S, Marriott M, Alexandrou E, Gresle M, Egan G, Kilpatrick T. 2010. Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade. Pharmacol Ther 126: 82-93.
64. Walter L, Stella N. 2004. Cannabinoids and neuroinflammation. Br J Pharmacol 141: 775-785.
65. Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C, Banati RR, Anand P. 2006. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 6: 12.
66. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A. 2003. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362: 1517-1526.